Carl L.G. Hansen, Ph.D., born in May 1973, is the CEO and co-founder of AbCellera Biologics Inc., a Canadian biotechnology company that focuses on antibody therapeutics. He has a strong background in biochemistry, holding a Ph.D. from the University of...

Carl L.G. Hansen, Ph.D., born in May 1973, is the CEO and co-founder of AbCellera Biologics Inc., a Canadian biotechnology company that focuses on antibody therapeutics. He has a strong background in biochemistry, holding a Ph.D. from the University of British Columbia. Prior to his role at AbCellera, he co-founded another biotechnological venture, Precision NanoSystems, and served as a professor at UBC, contributing over 65 research manuscripts in microfluidics and genomics. Under his leadership, AbCellera has made significant strides in accelerating the development of antibody medicines. In 2023, his total compensation was reported at around $714,939, a drop from $8.8 million in 2022, which was largely due to fluctuations in company performance and stock values. Dr. Hansen's substantial insider ownership of approximately 20.59% of AbCellera highlights his commitment to the company's success. He’s been effectively at the helm since 2012, aiming to tackle complex challenges in the drug development process.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other AbCellera Biologics Inc. CEOs

A

Carl Hansen

Founder and Ex-CEO of AbCellera Biologics Inc.

Education

PhD in Biochemistry from the University of British Columbia

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

May 15, 1973 - 52 years ago

CEO of AbCellera Biologics Inc. for

2 years 9 months (Dec 2020 - Oct 2023)

Previous Experience

Co-founder and CEO of AbCellera, former roles at the University of British Columbia and other biotech firms.

Rivals

Competitors/colleagues of Carl Hansen

Holdings

See how much did Carl Hansen make over time.

As of October 2023, Carl Hansen holds approximately 59.38 million shares in AbCellera, which constitutes about 20.59% of the company. His holdings have seen fluctuations, peaking during the company’s rapid growth after its 2020 IPO, where he transitioned from partial...

As of October 2023, Carl Hansen holds approximately 59.38 million shares in AbCellera, which constitutes about 20.59% of the company. His holdings have seen fluctuations, peaking during the company’s rapid growth after its 2020 IPO, where he transitioned from partial ownership to substantial wealth due to rising stock values. In 2022, his net worth was notably impacted as the stock price dropped, reflecting broader challenges in the market. However, his significant stake indicates a long-term commitment to the company's vision, aligning his wealth closely with the company's performance.

Total Stock Sold

$143.04M

ABCL

$143.04M

6,000,000 ABCL shares

What if they kept their stock?

If Carl Hansen didn't sell their stock, today they would have:
Extra ABCL6,000,000 shares worth $353.40M.
This is 147.06% and $210.36M more than what they got when they sold the stock.

Charitable Transactions

ABCL

2,223,500 shares

ABCL

Recent Charitable Transactions

ABCL

2,223,500 shares

ABCL

Dec 31, 2021

Charity

Insider Trading

See recent insider trades of Carl Hansen.

ABCL

2,223,500 shares

ABCL

Dec 31, 2021

Charity

ABCL

$148.59M

ABCL at $24.77/share

Jun 9, 2021

Sale

Compensation History

See how much did Carl Hansen make over time.

Carl Hansen’s compensation has varied significantly over the years. In 2022, he received a total of $8,797,688, primarily from bonuses and vested stock options linked to company performance. His 2022 package included a base salary of $450,000, a bonus of $239,023, and significant stock options valued at $8.09 million. However, in 2023, his compensation decreased to $714,939, driven by adjustments in the performance-based bonus structure and changing stock values. This drop indicates the volatile nature of the biotech industry and Hansen's keen focus on performance metrics, emphasizing fiscal prudence and shareholder alignment. Since the start of his tenure, Hansen has overseen both the growth of the company and the rise and fall of his compensation based on stock performance and company innovation.

Year

2022

Total Compensation

$1.20M

Salary

$450.00K

Board Justification

The compensation philosophy is designed to attract and retain top executive talent while aligning their interests with those of shareholders through performance-based incentives.

Bonus

$100.00K

Board Justification

The bonus is based on the achievement of specific performance metrics set by the Board of Directors for the fiscal year 2022.

Other

$50.00K

Board Justification

Other compensation includes health benefits and retirement contributions.

Restricted Stock

$600.00K(20K RSU)

Board Justification

The vested stock represents shares that were granted in previous years and became fully vested in 2022.

Performance Metrics

Performance metrics include revenue growth, operational efficiency, and achievement of strategic goals.

Other AbCellera Biologics Inc. CEOs

Here are other CEOs of AbCellera Biologics Inc.

Jenna T. Smith

CEO of AbCellera Biologics Inc.

October 2023 - Present